Prognostic Factors in Thymic Epithelial Tumors Undergoing Complete Resection

Zisis, Charalambos; Rontogianni, Dimitra; Tzavara, Chara; Stefanaki, Kalliopi; Chatzimichalis, Antonios; Loutsidis, Antonios; Iliadis, K.; Kontaxis, Argirios; Dosios, Theodosios; Bellenis, Ion

doi:10.1016/j.athoracsur.2005.03.093

Cited by 14 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…None of the patients with type B1 disease succumbed. Type A, AB and B1 disease, thus, had more favorable outcomes than type B2 and B3, consistent with the results of previous studies (11)(12)(13)15,16).…”

Section: Discussionsupporting

confidence: 82%

Surgical outcomes and reevaluation of treatment strategies for thymomas

Ito

Nakayama²,

Tsuboi³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

Abstract. Improved histological typing systems for thymic tumors and advances in induction and adjuvant therapy have created the need to reevaluate strategies for the management of thymoma. We retrospectively studied 73 patients with completely resected thymomas unassociated with myasthenia gravis. The World Health Organization (WHO) histologic classification, clinicopathological features and surgical outcomes were analyzed. Overall survival was 66.2% at 10 years, and the median survival time was 169 months. According to the Masaoka staging system, overall survival rates at 10 years were 94.7% in stage I, 76.1% in stage II, 30% in stage III and 0% in stage IV. In the WHO classification, overall survival rates at 10 years were 91.9% in types A and AB, 50.9% in type B2 and not achieved in type B3. The disease-free interval was slightly shorter in patients with B2 and B3 disease than in those with type A, AB and B1 disease. Advanced thymomas were significantly associated with type B2 and B3 (p<0.01). In stage III and IV disease, adjuvant or neoadjuvant therapy was associated with better survival as compared to no adjuvant therapy (p=0.07). On multivariate analysis, Masaoka stage III and IV disease and extended thymectomy indicated significant, negative and independent risk factors for survival (p<0.01). Masaoka stage I and II thymomas or WHO type A and AB thymomas have favorable prognoses and do not require postoperative adjuvant therapy. Patients with stage III and IV thymomas require additional therapy after surgery.

show abstract

Section: Discussionsupporting

confidence: 82%

Surgical outcomes and reevaluation of treatment strategies for thymomas

Ito

Nakayama²,

Tsuboi³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Furthermore, tumor invasiveness, recurrence, completeness of resection, and tumor-related death can occur more frequently in types AB, B2, B3, and C than in types A and B1. Others have determined that a simplified system wherein TETs are divided into only 2 types, WHO-type A/AB/B1 and WHO-type B2/B3/C, predicts prognosis and optimal therapy more consistently (8)(9)(10). In light of these findings, we have opted to analyze our data by pooling TETs using the 2-type histologic grading system rather than the 6-type WHO histologic criteria.…”

Section: Tissue Specimensmentioning

confidence: 93%

“…The modified Masaoka staging system is currently the most commonly employed scoring method, but its value is limited by the fact that it assigns scores only for specific macroscopic surgical, but not histologic, characteristics (1), making it difficult to reliably assess tumor severity in patients (2)(3)(4). The introduction in 1999 of the World Health Organization (WHO) histologic criteria (5), which scores tumor severity on the basis of epithelial cell morphology and the lymphocyte-to-epithelial cell ratio, stratified TETs into 6 entity types, A, AB, B1, B2, B3, and C, and provided a new means of predicting states of malignancy of TETs; however, controversies surrounding its accuracy still exist (2)(3)(4)(6)(7)(8)(9)(10). The insufficiencies of current staging systems are confounded by the fact that no genetic or epigenetic prognostic indicators have been proposed.…”

Section: Introductionmentioning

confidence: 99%

Aberrant DNA Methylation in Thymic Epithelial Tumors

Chen

Yin

Wei

et al. 2009

Cancer Investigation

View full text Add to dashboard Cite

Aberrant DNA methylation plays a critical role in the development and progression of many types of cancer. To investigate whether DNA methylation is abnormal in thymic epithelial tumors (TETs), we analyzed global methylation levels and the methylation status of 9 tumor suppressor gene (TSG) promoters in 65 TET samples. We found evidence of TSG promoter hypermethylation and decreased TSG expression in severe TETs. Furthermore, relative to early-stage TETs, global DNA methylation levels were reduced and DNA methyltransferase expression was increased in advanced-stage TETs. Our results suggest that aberrant DNA methylation is associated with TET development.

show abstract

“…MG varlığı, ileri yaş, tümör çapı (≥8 cm), hücre siklus protein ekspresyonu gibi birçok faktör ek prognostik faktör (PF) olarak tanım-lanmıştır (27)(28)(29) .…”

Section: Discussionunclassified

Prognostic Factors and Radiotherapy in Thymic Epithelial Tumors: A single institutional experience

Temelli¹,

Ekici²,

Kekilli³

2017

Okmeydani Medical Journal

View full text Add to dashboard Cite

Amaç: Timik epitelyal tümörler (TET) nadir görülür ve Material and Methods: We retrospectively analysed clinical features of TET and the correlation of World Health Organisation (WHO) histologic classification and Masaoka staging system with radiotherapy modalities in 18 patients from 2004 to 2015.Results: Our patients' male/female ratio was 10/8. Median age was 49 (range: 18-76). Fifteen patients were thymoma and 3 patients were thymic carcinoma. According to Masaoka staging; patients were distributed as Stage I 5.6% (n=1), Stage II 50% (n=9), Stage III 16.7% (n=3) and Stage IV 27,7% (n=5)

show abstract

Prognostic Factors in Thymic Epithelial Tumors Undergoing Complete Resection

Cited by 14 publications

References 29 publications

Surgical outcomes and reevaluation of treatment strategies for thymomas

Surgical outcomes and reevaluation of treatment strategies for thymomas

Aberrant DNA Methylation in Thymic Epithelial Tumors

Prognostic Factors and Radiotherapy in Thymic Epithelial Tumors: A single institutional experience

Contact Info

Product

Resources

About